MANTLE CELL LYMPHOMA

This study tested a combination of targeted therapy (acalabrutinib) and chemotherapy in 13 people with untreated mantle cell lymphoma, a rare blood cancer. The goal was to see if this approach could safely shrink tumors enough to allow a stem cell transplant. The treatment was gi…

This study tested a drug called obinutuzumab combined with chemotherapy (DHAP) and a stem cell transplant in 86 adults with mantle cell lymphoma, a rare blood cancer. After the transplant, patients received obinutuzumab as maintenance therapy to keep the cancer from coming back. …

This study tested a stem cell transplant from half-matched (haploidentical) family donors for people with various blood cancers. The treatment used a reduced-intensity chemotherapy and radiation regimen to prepare the body for the transplant. The goal was to see how many patients…

This study tested a two-part chemotherapy regimen (EDOCH alternating with DHAP) with or without the targeted drug rituximab in 55 younger adults (age 65 or under) newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal was to see if this approach improves how lon…

This study tested an experimental pill called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was…

This study tested whether giving the drug bortezomib after intensive chemotherapy, antibody therapy, and a stem cell transplant could help keep mantle cell lymphoma from coming back. 151 adults with untreated mantle cell lymphoma took part. The goal was to see if this approach im…

This study tested a new radiation therapy schedule for people with B-cell lymphoma that has come back or not responded to treatment. Participants received radiation once a week for five weeks before their CAR T-cell therapy. The goal was to see if this schedule makes radiation ea…

This study looked at a drug called zanubrutinib for people with certain types of B-cell lymphoma (like chronic lymphocytic leukemia or mantle cell lymphoma) who had to stop taking similar drugs (ibrutinib or acalabrutinib) because of bad side effects. The main goal was to see if …

This study tested a new drug (BGB-10188) alone or with other drugs in 97 people with certain blood cancers or advanced solid tumors. The goal was to find the safest and most effective dose. However, the best dose could not be determined for all groups because not enough data was …

This study tested different combinations of immune-suppressing drugs to prevent graft-versus-host disease (GVHD) in 174 patients with blood cancers who received a stem cell transplant from an unrelated donor. The goal was to find the most effective approach to reduce severe GVHD,…

This study tested whether replacing a standard transplant drug (cyclophosphamide) with a different drug (bendamustine) could make half-matched bone marrow transplants safer for people with blood cancers like leukemia and lymphoma. About 50 patients took part. The goal was to redu…

This early-stage study tested the safety and highest tolerable dose of a new, genetically modified immune cell therapy called PRGN-3007 UltraCAR-T in adults with advanced blood cancers and triple-negative breast cancer. The main goal was to see how much of the treatment patients …

This study created a registry of 227 adults with mantle cell lymphoma who had recently started a newer type of treatment. Researchers collected information on which drugs were used, how long people stayed on them, and how patients reported their quality of life. The goal was to u…

This study looked at whether PET scans can give doctors more accurate information about mantle cell lymphoma, a rare blood cancer, compared to standard CT scans and bone marrow biopsies. Researchers reviewed past data from 200 patients to see if PET scans could help predict how t…